Cluster headaches are known to frequently strike at the same hour every day. For instance, people often get headaches in the morning after sleeping for a few hours. People frequently get cluster headaches yearly for several years, which might last a lifetime. They often occur in the spring and fall, and they tend to occur at comparable periods of the year. Typically, if a brain scan for cluster headaches is expected, the diagnosis may be determined based only on patient symptoms without the need for additional testing.
To discuss the treatment choices after receiving a diagnosis of cluster headaches, patients would often consult a specialist, such as a neurologist (a doctor specializing in diseases of the brain and nervous system). The way cluster headaches impact patients give them their name. Most people first appear in clusters or groups before passing briefly. Although some headaches are shorter and others longer, they typically last 30 to 45 minutes each.
Throughout 24 hours, people can have up to eight of these headaches. And this might continue like this for days, weeks or even months. The clusters typically halt after that for unknown reasons. For months or years, the headaches go into remission before coming back. Nonetheless, some people never seem to have any fortune. They regularly (ongoingly) suffer from cluster headaches. One in five persons who suffer from cluster headaches experiences this.
One of Canada's most creative sectors is the pharmaceutical one. It is made up of businesses that create and produce new pharmaceuticals, generic medications, and over-the-counter medication goods. The industry is divided into several subsectors that cater to various industry segments. They consist of name-brand medicines, generic medications, small and medium-sized biopharmaceutical businesses (SMEs), contract research organizations (CROs), and contract manufacturing companies (CMOs). Canada is amongst the biggest sectorin the world for pharmaceutical sales, with a 2.1% share. The robust presence of the pharmaceutical industry, with the growing effectiveness of the cluster headache treatment drugs, is expected to surge the market expansion in the region.
The US market dominated the North America Cluster Headache Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $118.9 Million by 2028. The Canada market is poised to grow at a CAGR of 5.3% during (2022-2028). Additionally, The Mexico market should witness a CAGR of 5.1% during (2022-2028).
Based on Distribution channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies, and Others. Based on Type, the market is segmented Episodic, and Chronic. Based on Drug Class, the market is segmented into Triptans, Calcium Channel Blockers, Ergot Derivatives, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Dr. Reddy’s Laboratories Ltd., Novartis AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline PLC (GSK), Pfizer, Inc., Fresenius SE & Co. KGaA, Eli Lilly And Company, Grünenthal GmbH, and Arrotex Pharmaceuticals Pty Limited.
Scope of the Study
By Distribution channel
- Drug Stores & Retail Pharmacies
- Hospital Pharmacies
- Others
By Type
- Episodic
- Chronic
By Drug Class
- Triptans
- Calcium Channel Blockers
- Ergot Derivatives
- Others
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Dr.Reddy’s Laboratories Ltd.
- Novartis AG
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- GlaxoSmithKline PLC (GSK)
- Pfizer, Inc.
- Fresenius SE & Co. KGaA
- Eli Lilly And Company
- Grünenthal GmbH
- Arrotex Pharmaceuticals Pty Limited
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Cluster Headache Market, by Distribution channel
1.4.2 North America Cluster Headache Market, by Type
1.4.3 North America Cluster Headache Market, by Drug Class
1.4.4 North America Cluster Headache Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition & scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. North America Cluster Headache Market by Distribution channel
2.4 North America Drug Stores & Retail Pharmacies Market by Country
2.5 North America Hospital Pharmacies Market by Country
2.6 North America Others Market by Country
Chapter 4. North America Cluster Headache Market by Type
3.1 North America Episodic Market by Country
3.2 North America Chronic Market by Country
Chapter 5. North America Cluster Headache Market by Drug Class
4.1 North America Triptans Market by Country
4.2 North America Calcium Channel Blockers Market by Country
4.3 North America Ergot Derivatives Market by Country
4.4 North America Others Market by Country
Chapter 6. North America Cluster Headache Market by Country
5.1 US Cluster Headache Market
5.1.1 US Cluster Headache Market by Distribution channel
5.1.2 US Cluster Headache Market by Type
5.1.3 US Cluster Headache Market by Drug Class
5.2 Canada Cluster Headache Market
5.2.1 Canada Cluster Headache Market by Distribution channel
5.2.2 Canada Cluster Headache Market by Type
5.2.3 Canada Cluster Headache Market by Drug Class
5.3 Mexico Cluster Headache Market
5.3.1 Mexico Cluster Headache Market by Distribution channel
5.3.2 Mexico Cluster Headache Market by Type
5.3.3 Mexico Cluster Headache Market by Drug Class
5.4 Rest of North America Cluster Headache Market
5.4.1 Rest of North America Cluster Headache Market by Distribution channel
5.4.2 Rest of North America Cluster Headache Market by Type
5.4.3 Rest of North America Cluster Headache Market by Drug Class
Chapter 7. Company Profiles
6.1 Dr. Reddy’s Laboratories Ltd.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.2 Novartis AG
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.3 Sun Pharmaceutical Industries Ltd.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Regional & Segmental Analysis
6.3.4 Research & Development Expenses
6.4 Teva Pharmaceutical Industries Ltd.
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expenses
6.5 GlaxoSmithKline PLC (GSK)
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Research & Development Expense
6.6 Pfizer, Inc.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Regional & Segmental Analysis
6.6.4 Research & Development Expense
6.7 Fresenius SE & Co. KGaA
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Segmental and Regional Analysis
6.7.4 Research & Development Expenses
6.8 Eli Lilly And Company
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Regional Analysis
6.8.4 Research & Development Expenses
6.9 Grünenthal GmbH
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Segmental and Regional Analysis
6.9.4 Research & Development Expenses
7.10. Arrotex Pharmaceuticals Pty Limited
6.10.1 Company Overview
Companies Mentioned
- Dr. Reddy’s Laboratories Ltd.
- Novartis AG
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- GlaxoSmithKline PLC (GSK)
- Pfizer, Inc.
- Fresenius SE & Co. KGaA
- Eli Lilly And Company
- Grünenthal GmbH
- Arrotex Pharmaceuticals Pty Limited
Methodology
LOADING...